CRM

Salesforce

$180.62

-1.47%
Nov 20, 2026
Bobby Quantitative Model
Salesforce, Inc. is the leading provider of enterprise cloud software, anchored by its Customer 360 platform, which unifies sales, service, marketing, commerce, and data integration (MuleSoft) capabilities into a single system of record for enterprise customers. The company is the dominant incumbent in the customer relationship management (CRM) software market, with a platform ecosystem and installed base that make it a de facto standard for large organizations, though it increasingly positions itself as an AI-first application layer rather than a pure seat-based SaaS vendor. The current investor narrative is defined by two competing forces: an aggressive capital-return and margin-expansion story — highlighted by a roughly $25 billion buyback program and a forward earnings multiple that bulls argue is deeply undervalued — against persistent skepticism about decelerating subscription growth and whether Agentforce and other AI products can monetize fast enough to offset seat-compression fears. The recently announced all-cash acquisition of Braze for $47.50 per share adds a strategic customer-engagement asset but also introduces integration and dilution questions, while the stock's sharp single-day drop on the latest data date underscores how fragile sentiment remains around the AI transition.

People also watch

Sarcos

Sarcos

STRC

Analysis
Meta Platforms, Inc. Depositary Shares representing a 1/20th Interest in a Share of Series A Mandatory Convertible Preferred Stock

Meta Platforms, Inc. Depositary Shares representing a 1/20th Interest in a Share of Series A Mandatory Convertible Preferred Stock

METAM

Analysis
Uber

Uber

UBER

Analysis
Automatic Data Processing

Automatic Data Processing

ADP

Analysis
ServiceNow

ServiceNow

NOW

Analysis

BobbyInvestment Opinion: Should I buy CRM Today?

Rating: Hold with a constructive, valuation-anchored bias. The core thesis is that Salesforce is a 77.68%-gross-margin, $15.15 billion free-cash-flow franchise trading at 12.15x forward earnings and 4.86x sales — a multiple that prices in stagnation while the sell-side consensus of $287.08 implies 47.6% upside — but the near-term tape (-9.45% single-session breakdown, -19.19% one month, -23.30% YTD) and unresolved AI seat-compression debate argue against chasing the stock before evidence of reacceleration. The 41 Buy / 14 Hold / 1 Sell split (recommendation mean 1.68) supports accumulating on stabilization rather than buying the falling knife.

Supporting evidence is stacked on the value side of the ledger: forward PE of 12.15x versus trailing 27.04x implies consensus EPS of $25.37, a roughly 55% earnings step-up driven by a share count that fell from 962 million to 821 million diluted (about -15%) on $27.248 billion of buybacks; revenue grew 10.83% year-over-year to $11.345 billion with operating margin at 20.55% and EBITDA of $5.991 billion; trailing free cash flow is $15.154 billion against a $201.7 billion market cap; and the PEG of 1.24, EV/EBITDA of 16.08x, and P/CF of 13.45x all sit well below premium application-software norms. The $165.00 low analyst target is only about 15% below the current $194.52, while the $475.00 high target implies +144%, an asymmetric skew that favors patient holders.

Three risks could invalidate the thesis: (1) earnings quality — $2.221 billion of the latest quarter's $4.552 billion pre-tax income came from other income, so the 31.08% net margin overstates operating power and the 12.15x forward multiple may rest on optimistic EPS; (2) growth — subscription is 95.4% of revenue and growth is only 10.83%, so any AI-driven seat compression hits nearly the entire top line; (3) balance sheet and integration — a current ratio of 0.76 plus the all-cash Braze deal at $47.50 per share consumes flexibility. The rating would upgrade to Buy on a close above the $214.83 breakdown level accompanied by subscription growth above 12%, and would downgrade to Sell on a break below the $165.00 analyst low or evidence of forward EPS cuts. Verdict: undervalued relative to its own history (PE down from 47.99x in January 2025) and to peers, but fairly-to-cheaply valued only if the forward EPS estimate holds — a value opportunity with a catalyst problem, not a momentum trade.

Sign up to view all

CRM 12-Month Price Forecast

The forward-looking picture is a tug-of-war between a genuinely cheap multiple and a deteriorating growth and momentum profile. On valuation, 12.15x forward earnings, 4.86x sales, 16.08x EV/EBITDA, and a 1.24 PEG for a 77.68%-gross-margin franchise with $15.15 billion of trailing free cash flow are hard to dismiss, and the $287.08 consensus target plus the $165.00 low target create a favorable risk/reward skew of roughly 48% upside to 15% downside. Against that, growth of 10.83% is barely above the level that justifies a value multiple, the latest 31.08% net margin leans on $2.221 billion of other income, and the stock is in active distribution with a 43.61% max drawdown and -27.96 points of one-year relative weakness. The base case (55% probability) assumes growth stabilizes and the multiple holds, producing a recovery toward $215-$260; the bull case (25%) requires AI monetization to reaccelerate growth, and the bear case (20%) is a retest of $146-$165 if estimates are cut. I would upgrade to bullish on a close above $214.83 with subscription growth above 12%, and downgrade to bearish on a break below $165.00 or any cut to the $25.37 forward EPS consensus.

Historical Price
Current Price $180.62
Average Target $237.50
High Target $350.00
Low Target $146.32

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Salesforce's 12-month outlook, with a consensus price target around $286.14 and implied upside of +58.4% versus the current price.

Average Target

$286.14

56 analysts

Implied Upside

+58.4%

vs. current price

Analyst Count

56

covering this stock

Price Range

$165 - $475

Analyst target range

Buy
41 (73%)
Hold
14 (25%)
Sell
1 (2%)

Coverage is broad and overwhelmingly constructive: 53 analysts rate the stock, with 41 Buy, 14 Hold, and just 1 Sell, producing a recommendation mean of 1.68 (buy) and a consensus rating of "buy." The average target price of $287.08 implies roughly +47.6% upside from the current $194.52 — a strikingly bullish signal given the stock's recent collapse, and one that suggests the sell-side views the drawdown as an overreaction rather than a fundamental reset. The consensus leans clearly bullish, though the gap between price and target is wide enough to warrant skepticism about stale estimates.

The target range is extraordinarily wide — from a low of $165.00 (about -15% downside) to a high of $475.00 (roughly +144% upside) — signaling high uncertainty and low conviction in any single price point. The high target likely assumes successful Agentforce monetization, multiple re-expansion toward historical software norms, and buyback-driven EPS compounding; the low target prices in continued subscription deceleration, AI-driven seat compression, and Braze integration friction. Institutional actions are mixed but show a notable positive catalyst: BofA Securities upgraded to Buy from Underperform on 2026-10-12, while most other firms (DA Davidson, Cantor Fitzgerald, Wells Fargo, Citigroup, RBC) maintained existing Neutral/Equal Weight/Sector Perform stances — a pattern of stabilization rather than broad-based upgrading. The wide spread and predominantly hold/maintain posture indicate the market is waiting for proof that AI products can reaccelerate growth before re-rating the stock.

Drowning in data?

Find the real signal!

Bulls vs Bears: CRM Investment Factors

The bear case currently has stronger near-term evidence: a -9.45% single-session breakdown, -19.19% one-month performance, -15.15 points of relative weakness versus SPY, and a 43.61% max drawdown describe a stock in active distribution, not a bottoming pattern. The bull case rests on valuation and capital return rather than momentum — a 12.15x forward PE, 47.6% implied upside to the $287.08 consensus target, 41 Buy ratings out of 53, and a share count cut roughly 15% year-over-year. The single most important tension is whether Agentforce and AI monetization can reaccelerate subscription growth above the current 10.83% before seat-compression fears harden into estimate cuts; if that resolves positively the multiple re-rates, and if it does not, the 12.15x forward PE is a value trap rather than a discount. Note also that the 31.08% net margin is partly an artifact of $2.221 billion in other income, so the quality-of-earnings debate matters as much as the growth debate.

Bullish

  • Forward PE of 12.15x is deeply compressed: The trailing PE of 27.04x collapses to a forward PE of 12.15x, a roughly 55% compression that implies consensus EPS of $25.37 versus the trailing figure. For a franchise with 77.68% gross margins and $15.15 billion in trailing free cash flow, that multiple is closer to a mature industrial than a category-leading software platform.
  • Analyst consensus implies 47.6% upside: Of 53 covering analysts, 41 rate Buy versus 14 Hold and just 1 Sell, producing a recommendation mean of 1.68. The $287.08 average target sits 47.6% above the $194.52 close, and the $165.00 low target is only about 15% below — an asymmetric skew that suggests the sell-side views the selloff as an overreaction.
  • Margins expanded sharply year-over-year: Latest-quarter net income of $3.526 billion produced a 31.08% net margin versus 18.43% a year earlier, while operating margin held at 20.55% and EBITDA reached $5.991 billion. Even stripping out the $2.221 billion other-income line, operating income of $2.331 billion on $11.345 billion of revenue is a durable profitability base.
  • $25 billion buyback compounds EPS: Diluted shares fell from 962 million in the July 2025 quarter to 821 million in the July 2026 quarter — roughly a 15% reduction — as the company deployed $27.248 billion on repurchases. That shrinkage is the mechanical engine behind the trailing-to-forward EPS gap and supports the 12.15x forward multiple.

Bearish

  • Revenue growth stuck at 10.83%: Latest-quarter revenue of $11.345 billion grew 10.83% year-over-year, only a marginal acceleration from $11.201 billion in the January 2026 quarter. With Subscription and Support at $10.82 billion — 95.4% of revenue — there is essentially no diversification buffer if seat expansion stalls.
  • Decisive technical breakdown on volume: The stock fell 9.45% in a single session from $214.83 to $194.52 on 13.34 million shares, leaving it 19.19% lower over one month and 23.30% down year-to-date. It sits at roughly 39% of its 52-week range with a 43.61% maximum drawdown, and one-month relative strength of -15.15 points versus SPY confirms active distribution.
  • Current ratio of 0.76 signals liquidity tightness: Current liabilities exceed current assets, swollen by deferred revenue and a $24.712 billion debt repayment alongside $27.248 billion of buybacks. Q2 free cash flow of just $1.098 billion against $6.556 billion in Q1 shows how seasonal and buyback-dependent the cash profile has become.
  • Latest margin flattered by non-operating gain: Pre-tax income of $4.552 billion versus operating income of $2.331 billion means $2.221 billion of the quarter's profit came from other income, not operations. Gross margin also slipped to 76.65% from 78.10% a year earlier, so the headline 31.08% net margin overstates underlying earnings power.

CRM Technical Analysis

Salesforce is in a structurally damaged intermediate-term trend despite a powerful mid-year rally. The stock is down 17.93% over the trailing year and 23.30% year-to-date, and at $194.52 it sits at roughly 39% of its 52-week range (low $146.32, high $269.11) — closer to the bottom than the top, signaling that the long-term trend remains one of distribution rather than accumulation. The 43.61% maximum drawdown confirms this is not a shallow pullback but a full bear-cycle retracement, meaning rallies should be treated as suspect until proven otherwise.

Short-term momentum has deteriorated sharply and is diverging violently from the six-month trend. The stock is down 19.19% over the past month versus a 5.61% decline over three months, yet it is still up 10.33% over six months — a classic pattern of a rally that has rolled over. The single-session collapse of -9.45% (from $214.83 to $194.52) on elevated volume of 13.34 million shares is a decisive breakdown candle, and the 1-month relative strength of -15.15 percentage points versus SPY confirms severe underperformance. With the 1-year relative strength at -27.96 points against a +10.03% SPY gain, capital is actively rotating out of this name.

Key technical levels are now clearly defined. Immediate support sits at the 52-week low of $146.32, roughly 25% below the current price; a break there would signal a new leg lower and likely trigger momentum-driven selling. Resistance is layered: the $214.83 prior close and the $230–$250 congestion zone from October, with the 52-week high of $269.11 as the major ceiling. A beta of 1.233 means the stock is about 23% more volatile than the market, so position sizing should account for amplified drawdowns — a 10% SPY decline would imply roughly a 12%+ move here, and the short ratio of 3.52 suggests short interest is meaningful but not extreme.

Beta

1.23

1.23x market volatility

Max Drawdown

-43.6%

Largest decline past year

52-Week Range

$146-$269

Price range past year

Annual Return

-19.9%

Cumulative gain past year

PeriodCRM ReturnS&P 500
1m-25.3%-9.7%
3m-13.6%-9.9%
6m+0.3%-7.5%
1y-19.9%+4.7%
ytd-28.8%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

CRM Fundamental Analysis

Revenue growth remains positive but is decelerating in absolute terms. The most recent quarter (period ending 2026-07-31) delivered $11.345 billion in revenue, up 10.83% year-over-year, a modest acceleration from the $11.201 billion reported in the January 2026 quarter and the $11.133 billion in the April 2026 quarter. The sequential progression from $10.236 billion (July 2025) to $11.345 billion (July 2026) shows steady mid-single-to-low-double-digit expansion, with Subscription and Support at $10.82 billion (95.4% of revenue) and Professional Services at just $525 million — meaning growth is almost entirely dependent on the core subscription engine, leaving little diversification buffer if seat expansion stalls.

Profitability is robust and improving. The latest quarter produced $3.526 billion in net income on a 31.08% net margin, a dramatic step up from $1.887 billion and an 18.43% margin in the year-ago quarter, while gross margin held steady at 76.65% (versus 78.10% a year earlier). Operating margin came in at 20.55%, and EBITDA of $5.991 billion represented a 52.81% EBITDA ratio — an unusually high figure that reflects the large non-operating gain embedded in pre-tax income ($4.552 billion versus $2.331 billion operating income). The trailing net margin of 17.96% and operating margin of 20.06% are healthy for application software, though investors should note the latest quarter's margin was flattered by a $2.221 billion other-income line rather than pure operating leverage.

Balance sheet and cash generation are solid but not fortress-like. Debt-to-equity is low at 0.29, ROE is 12.61%, and ROA is 5.70%, while trailing free cash flow is a substantial $15.154 billion. However, the current ratio of 0.76 is below 1.0, indicating that current liabilities — swollen by deferred revenue and the Q1 debt repayment of $24.712 billion alongside $27.248 billion in buybacks — exceed current assets, which is typical for subscription businesses but still a liquidity consideration. The Q2 free cash flow of just $1.098 billion was seasonally weak against $6.556 billion in Q1, and with a dividend payout ratio of 21.28% and a modest 0.79% yield, the company is prioritizing buybacks over income — a capital allocation stance that supports EPS but leaves less cushion if operating cash flow softens.

Quarterly Revenue

$11.3B

2026-07

Revenue YoY Growth

+10.8%

YoY Comparison

Gross Margin

76.6%

Latest Quarter

Free Cash Flow

$15.2B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Subscription and Support
Professional Services and Other

Open an Account, get $2 TSLA now!

Valuation Analysis: Is CRM Overvalued?

Because Salesforce is solidly profitable (net income of $3.526 billion in the latest quarter), the PE ratio is the appropriate primary metric. The trailing PE is 27.04x, but the forward PE of just 12.15x is the critical number — a roughly 55% compression that implies the market expects earnings to more than double, consistent with consensus EPS estimates of $25.37 versus the trailing figure. That enormous trailing-to-forward gap signals the market is pricing in either substantial buyback-driven EPS accretion or one-time gains rolling off, and it is the single strongest bull argument in the data set.

On peer-relative grounds, the stock screens cheap for a category leader. The PS ratio of 4.86x and EV/Sales of 4.73x are modest for a 77% gross-margin software franchise, and the PEG ratio of 1.24 suggests growth is reasonably priced. The EV/EBITDA of 16.08x is well below the premium multiples typically commanded by large-cap application software, while the P/B of 3.41x and P/CF of 13.45x reinforce the value framing. Against a sector where high-growth SaaS names often trade at 8–15x sales, Salesforce's ~4.9x PS represents a meaningful discount that the market is applying for slower growth and AI disruption risk.

Historically, the stock is near the low end of its own valuation band. The current trailing PE of 27.04x compares with 47.99x in the January 2025 quarter, 41.73x in April 2025, and 32.78x in July 2025 — a clear multi-quarter de-rating. Similarly, the PS ratio has compressed from 32.79x (January 2025) to 24.24x (October 2025) to 17.72x (January 2026) and now 4.86x, though the most recent historical reading of 13.30x (July 2026) suggests the current 4.86x figure may reflect a different share-count or data basis and should be treated cautiously. Either way, the direction is unambiguous: the market has steadily marked down the multiple, which is either a deep value opportunity or a signal of structural growth concerns — the forward PE of 12.15x argues the former has merit.

PE

27.0x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 11x~247x

vs. Industry Avg

31.1x

Industry PE ~31.1x*

EV/EBITDA

16.1x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on growth concentration and earnings quality. Subscription and Support is 95.4% of the $11.345 billion quarterly revenue base, so any seat-compression from AI-driven pricing models hits almost the entire top line, and growth is already only 10.83% year-over-year. The latest quarter's 31.08% net margin was flattered by $2.221 billion of other income against $2.331 billion of operating income, meaning underlying operating profitability is roughly half the headline, while gross margin slipped to 76.65% from 78.10%. Liquidity is a secondary concern: the current ratio of 0.76 is below 1.0 after a $24.712 billion debt repayment and $27.248 billion of buybacks, and Q2 free cash flow of $1.098 billion versus $6.556 billion in Q1 shows how dependent the cash story is on seasonal collections.

Market and competitive risks are dominated by multiple compression and AI disruption. The stock carries a beta of 1.233, so a 10% SPY decline implies roughly a 12%+ move here, and the trailing PE has already de-rated from 47.99x in January 2025 to 27.04x — a market that has been steadily marking the franchise down. The Braze acquisition at $47.50 per share in cash adds integration execution risk and consumes balance-sheet flexibility at a moment when the current ratio is already tight, and coverage remains mostly Hold/Maintain with only BofA upgrading on 2026-10-12. The 1-year relative strength of -27.96 points against a +10.03% SPY gain shows capital is rotating out of the name, and a short ratio of 3.52 means there is enough short interest to amplify further downside on bad news.

In a worst-case scenario, Agentforce monetization disappoints, subscription growth decelerates toward high single digits, and the Braze integration distracts management while buyback-driven EPS accretion is offset by a lower multiple. The stock would retest the 52-week low of $146.32, roughly 25% below the current $194.52, and the analyst low target of $165.00 implies about 15% downside as a nearer-term marker. A full retracement to the 52-week low would represent a loss of roughly -25% from here, and given the 43.61% maximum drawdown already recorded, a further leg lower toward the $146 area is a realistic rather than extreme outcome if estimates are cut.

FAQ

Ranked by severity: first, growth concentration — Subscription and Support is 95.4% of the $11.345 billion quarterly revenue base and growth is only 10.83%, so any AI-driven seat compression hits nearly the entire top line and would force the forward EPS cuts that invalidate the 12.15x multiple. Second, earnings quality — the latest quarter's 31.08% net margin rests on $2.221 billion of other income against $2.331 billion of operating income, and gross margin slipped to 76.65% from 78.10%, so underlying profitability is roughly half the headline and the forward multiple may be built on optimistic EPS. Third, balance sheet and integration — a current ratio of 0.76 is below 1.0 after a $24.712 billion debt repayment and $27.248 billion of buybacks, and the all-cash Braze deal at $47.50 per share consumes further flexibility while adding execution risk. Fourth, market and momentum — a beta of 1.233, a 43.61% max drawdown, -27.96 points of one-year relative weakness versus a +10.03% SPY gain, and a 3.52 short ratio mean further bad news could be amplified by both index correlation and short interest.

The scenario framework assigns 55% to a base case of $215-$260, 25% to a bull case of $287-$350, and 20% to a bear case of $146.32-$165.00. The base case — the most likely outcome — assumes subscription growth stabilizes near 10.83%, the Braze integration proceeds without guidance cuts, and buyback-driven EPS accretion keeps the forward multiple at 12-14x, letting the stock grind back into the $230-$250 October congestion zone without a full re-rating. The bull case requires Agentforce and AI products to push growth back above 12% and validate the $25.37 forward EPS, re-expanding the multiple toward 14-16x and carrying the stock to the $287.08 consensus and potentially $350. The bear case is an AI seat-compression and estimate-cut spiral that retests the $165.00 analyst low and then the $146.32 52-week low, roughly -15% to -25% from the current $194.52. The key assumption behind the most likely path is that the forward EPS consensus holds — if it does, the skew is roughly 48% upside to 15% downside.

On most measures the stock screens undervalued relative to its own history and to large-cap application-software norms. The trailing PE has de-rated from 47.99x in January 2025 to 41.73x, 32.78x, and now 27.04x, while PS has compressed from 32.79x to 4.86x and EV/EBITDA sits at 16.08x — well below the premium multiples typically commanded by category leaders. The forward PE of 12.15x is the pivotal number: it implies consensus EPS of $25.37 versus the trailing figure, a roughly 55% step-up that depends on buyback-driven share-count reduction (962 million to 821 million diluted) and on the $2.221 billion other-income gain rolling off cleanly. The market is therefore paying a discount that implies it expects stagnation, not decline — but that discount is only genuine value if the forward EPS estimate holds. If estimates are cut, the 12.15x multiple becomes a value trap rather than a bargain, which is why the stock trades at a persistent discount despite 41 Buy ratings.

From a risk/reward standpoint the skew is favorable but the timing is not: at $194.52 the stock sits roughly 47.6% below the $287.08 analyst average target while the $165.00 low target is only about 15% below, and the 52-week low of $146.32 caps realistic downside near -25%. The valuation support is real — 12.15x forward earnings, 4.86x sales, 16.08x EV/EBITDA, a 1.24 PEG, and $15.15 billion of trailing free cash flow for a 77.68%-gross-margin franchise — and 41 of 53 analysts rate it Buy with a 1.68 recommendation mean. The offset is that the stock just broke down 9.45% in a single session on 13.34 million shares, is -19.19% over one month with -15.15 points of relative weakness versus SPY, and growth of 10.83% is barely above what justifies a value multiple. It is a good buy for patient, valuation-anchored investors willing to scale in over weeks and tolerate a retest of $165, and a poor buy for anyone who needs momentum confirmation or cannot stomach a beta of 1.233 amplifying market drawdowns.

The profile favors long-term holding with staged entry rather than short-term trading. The company is a mature, profitable franchise — $15.15 billion trailing free cash flow, 20.55% operating margin, low 0.29 debt-to-equity, and a 0.79% dividend yield with a conservative 21.28% payout ratio — whose return driver is multiple recovery plus buyback-driven EPS compounding, not quarterly momentum. Short-term traders face a hostile tape: a -9.45% single-session breakdown, -19.19% one-month performance, -15.15 points of one-month relative weakness versus SPY, and a beta of 1.233 that amplifies market moves by roughly 23%. Earnings visibility is moderate — the $25.37 forward EPS consensus is a 55% step-up from trailing and depends on share-count reduction and the other-income line normalizing — so a suggested minimum holding period is 18-24 months, long enough for the Braze integration to annualize and for at least four to six quarters of subscription growth data to confirm or refute the AI seat-compression thesis. Position sizing should reflect the 43.61% max drawdown already recorded and the possibility of a retest of $165 before the recovery takes hold.